BridgeBio Pharma

General Information


We are a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. We founded BridgeBio in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Our pipeline of over 15 development programs includes product candidates ranging from early discovery to late-stage development.

Employees: 152
Founded: 2015
Contact Information
Address 421 Kipling Street, Palo Alto, CA 94301, US
Phone Number (650) 391-9740
Web Address
View Prospectus: BridgeBio Pharma
Financial Information
Market Cap $2048.5mil
Revenues $0 mil (last 12 months)
Net Income $-167.9 mil (last 12 months)
IPO Profile
Symbol BBIO
Exchange NASDAQ
Shares (millions): 20.5
Price range $17.00 - $17.00
Est. $ Volume $348.5 mil
Manager / Joint Managers J.P. Morgan/ Goldman Sachs/ Jefferies/ SVB Leerink/ KKR
CO-Managers Piper Jaffray/ Mizuho Securities/ BMO Capital Markets/ Raymond James
Expected To Trade: 6/27/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change